Retinoblastoma (RB) is prone to delayed diagnosis or treatment and has an increased likelihood of metastasizing. Thus, it is crucial to perform an effective imaging examination and provide optimal treatment of RB to prevent metastasis. Nanoparticles that support diagnostic imaging and targeted therapy are expected to noninvasively integrate tumor diagnosis and treatment. Herein, we report a multifunctional nanoparticle for multimodal imaging-guided low-intensity focused ultrasound (LIFU)/immunosynergistic RB therapy. Magnetic hollow mesoporous gold nanocages (AuNCs) conjugated with Fe3O4 nanoparticles (AuNCs–Fe3O4) were prepared to encapsulate muramyl dipeptide (MDP) and perfluoropentane (PFP). The multimodal imaging capabilities, antitumor effects, and dendritic cell (DC) activation capacity of these nanoparticles combined with LIFU were explored in vitro and in vivo. The biosafety of AuNCs–Fe3O4/MDP/PFP was also evaluated systematically. The multifunctional magnetic nanoparticles enhanced photoacoustic (PA), ultrasound (US), and magnetic resonance (MR) imaging in vivo and in vitro, which was helpful for diagnosis and efficacy evaluation. Upon accumulation in tumors via a magnetic field, the nanoparticles underwent phase transition under LIFU irradiation and MDP was released. A combined effect of AuNCs–Fe3O4/MDP/PFP and LIFU was recorded and verified. AuNCs–Fe3O4/MDP/PFP enhanced the therapeutic effect of LIFU and led to direct apoptosis/necrosis of tumors, while MDP promoted DC maturation and activation and activated the ability of DCs to recognize and clear tumor cells. By enhancing PA/US/MR imaging and inhibiting tumor growth, the multifunctional AuNC–Fe3O4/MDP/PFP nanoparticles show great potential for multimodal imaging-guided LIFU/immunosynergistic therapy of RB. The proposed nanoplatform facilitates cancer theranostics with high biosafety.

A 3.1% Ru/UiO-66 material was prepared by adsorption of RuCl 3 from ethyl acetate on to MOF UiO-66, followed by reduction with NaBH 4 . The presence of acid–base and ox-red sites allows this 3.1% Ru/UiO-66 material acting as a bifunctional catalyst for the reduction of nitroarenes and tandem reaction of alcohol oxidation/Knoevenagel condensation. The high efficiency of 3.1% Ru/UiO-66 was demonstrated in the reduction of nitroarenes to amines. This system can be applied as a catalyst for at least six successive cycles without loss of activity. The 3.1% Ru/UiO-66 catalyst also was active in the tandem aerobic oxidation of alcohols/Knoevenagel condensation with malononitrile. However, the activity of this catalyst strongly decreased in the second cycle. A combination of physicochemical and catalytic experimental data indicated that Ru nanoparticles are the active sites both for the catalytic reduction of nitro compounds and the aerobic oxidation of alcohols. The activity for the Knoevenagel condensation reaction was from the existence of the “Zr n + –O 2– Lewis acid–base” pair in the framework of UiO-66.

This study demonstrates the characteristics of brain MRI abnormalities in Chinese NMO patients, which are helpful to the revision of diagnostic criteria for NMO.

No abstract